Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -100%. A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.06 per share when it actually produced a loss of $0.04, delivering a surprise of 33.33%.Over the last four quar ...